Compare LUNG & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LUNG | KRRO |
|---|---|---|
| Founded | 1995 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.2M | 101.1M |
| IPO Year | 2020 | 2019 |
| Metric | LUNG | KRRO |
|---|---|---|
| Price | $1.47 | $10.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 12 |
| Target Price | $6.81 | ★ $47.10 |
| AVG Volume (30 Days) | ★ 376.4K | 143.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 10.00 | ★ 82.35 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $83,789,000.00 | $2,271,000.00 |
| Revenue This Year | $9.21 | $145.97 |
| Revenue Next Year | $5.03 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 22.01 | N/A |
| 52 Week Low | $1.31 | $5.20 |
| 52 Week High | $8.71 | $55.89 |
| Indicator | LUNG | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 39.99 | 43.29 |
| Support Level | $1.34 | $10.55 |
| Resistance Level | $1.93 | $12.54 |
| Average True Range (ATR) | 0.10 | 0.84 |
| MACD | 0.03 | -0.14 |
| Stochastic Oscillator | 29.51 | 4.67 |
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.